10 reports of this reaction
1.6% of all BACITRACIN ZINC AND POLYMYXIN B SULFATE reports
#8 most reported adverse reaction
HYPERSENSITIVITY is the #8 most commonly reported adverse reaction for BACITRACIN ZINC AND POLYMYXIN B SULFATE, manufactured by Kenvue Brands LLC. There are 10 FDA adverse event reports linking BACITRACIN ZINC AND POLYMYXIN B SULFATE to HYPERSENSITIVITY. This represents approximately 1.6% of all 622 adverse event reports for this drug.
Patients taking BACITRACIN ZINC AND POLYMYXIN B SULFATE who experience hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERSENSITIVITY is a less commonly reported adverse event for BACITRACIN ZINC AND POLYMYXIN B SULFATE, but still significant enough to appear in the safety profile.
In addition to hypersensitivity, the following adverse reactions have been reported for BACITRACIN ZINC AND POLYMYXIN B SULFATE:
The following drugs have also been linked to hypersensitivity in FDA adverse event reports:
HYPERSENSITIVITY has been reported as an adverse event in 10 FDA reports for BACITRACIN ZINC AND POLYMYXIN B SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERSENSITIVITY accounts for approximately 1.6% of all adverse event reports for BACITRACIN ZINC AND POLYMYXIN B SULFATE, making it a notable side effect.
If you experience hypersensitivity while taking BACITRACIN ZINC AND POLYMYXIN B SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.